Targeting ApoC-III to Reduce Coronary Disease Risk (Q38904497)

7 September 2017

1 reference

title

Targeting ApoC-III to Reduce Coronary Disease Risk (English)

1 reference

7 September 2017

Sumeet A Khetarpal

1

1 reference

7 September 2017

Arman Qamar

series ordinal

2

1 reference

7 September 2017

John S Millar

series ordinal

3

1 reference

7 September 2017

Daniel J Rader

series ordinal

4

1 reference

7 September 2017

publication date

1 September 2016

1 reference

Current Atherosclerosis Reports

7 September 2017

published in

1 reference

7 September 2017

volume

18

1 reference

7 September 2017

issue

9

1 reference

7 September 2017

page(s)

54

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-016-0609-y

7 September 2017

exact match

0 references

cites work

Decade in review--dyslipidaemia: Resurgence of targets and compounds to treat dyslipidaemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Vascular disease risk in patients with hypertriglyceridemia: endothelial progenitor cells, oxidative stress, accelerated senescence, and impaired vascular repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Discovery and refinement of loci associated with lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Common variants associated with plasma triglycerides and risk for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Remnant cholesterol as a causal risk factor for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Physiological regulation of lipoprotein lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

A century of cholesterol and coronaries: from plaques to genes to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Nonstatin therapies for management of dyslipidemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Recent advances in pharmacotherapy for hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Peroxisome proliferator activated receptors and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Genetic Variation Determines PPARγ Function and Anti-diabetic Drug Response In Vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Thiazolidinediones and the liver in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Molecular identification of high and low affinity receptors for nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Molecular identification of nicotinic acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

A COMPARISON OF THE EFFECTS OF ETHYL CHLOROPHENOXYISOBUTYRATE AND NICOTINIC ACID ON PLASMA FREE FATTY ACIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

STUDIES ON THE RELATION BETWEEN MOBILIZATION OF FREE FATTY ACIDS AND ENERGY METABOLISM IN MAN: EFFECTS OF NOREPINEPHRINE AND NICOTINIC ACID.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

PLASMA TRIGLYCERIDE CONCENTRATION AND PLASMA FREE FATTY ACID CHANGES IN RESPONSE TO NOREPINEPHRINE IN MAN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of extended-release niacin with laropiprant in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Safety profile of extended-release niacin in the AIM-HIGH trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Antisense technologies. Improvement through novel chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Progress in antisense technology: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0609-Y

Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity

21 January 2018

1 reference

12 December 2020

Postprandial lipoproteins and atherosclerosis

1 reference

12 December 2020

Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia

1 reference

12 December 2020

Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis

1 reference

12 December 2020

EFFECT OF NICOTINIC ACID ON THE TURNOVER RATE AND OXIDATION OF THE FREE FATTY ACIDS OF PLASMA IN MAN DURING EXERCISE

1 reference

12 December 2020

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression

1 reference

12 December 2020

INHIBITION OF THE MOBILIZATION OF FREE FATTY ACIDS FROM ADIPOSE TISSUE IN DIABETES. I. EFFECT OF NICOTINIC ACID ON THE ALLOXAN-DIABETIC STATE IN RATS

1 reference

12 December 2020

INHIBITION OF THE MOBILIZATION OF FREE FATTY ACIDS FROM ADIPOSE TISSUE IN DIABETES. II. EFFECT OF NICOTINIC ACID AND ACETYLSALICYLATE ON BLOOD GLUCOSE IN HUMAN DIABETICS

1 reference

12 December 2020

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

1 reference

12 December 2020

Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia

1 reference

12 December 2020

Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

1 reference

12 December 2020

Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.

1 reference

12 December 2020

Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration

1 reference

12 December 2020

Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action

1 reference

12 December 2020

THE EFFECTS OF NICOTINIC ACID, PHENTOLAMINE AND NETHALIDE ON THE PLASMA FREE FATTY ACIDS AND THE BLOOD PRESSURE IN THE DOG. A COMPARATIVE STUDY

1 reference

12 December 2020

Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice

1 reference

12 December 2020

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease

1 reference

12 December 2020

The Effect of Nicotinic Acid on the Plasma Free Fatty Acids Demonstration of a Metabolic Type of Sympathicolysis

1 reference

12 December 2020

10.1007/S11883-016-0609-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1032437640

0 references

1 reference